New antiviral agents for the treatment and/or prevention of diseases caused by viruses, such as Ebola (EBOV) and African swine fever (ASF)

The CSIC, FIB Hospital 12 de Octubre and INIA have identified the use of a family of chemical compounds as antiviral agents, being useful for the treatment of viral diseases such as those caused by the Ebola virus (EBOV) and the African swine fever virus (ASF).

Pharmaceutical companies are being sought to collaborate through a patent licence agreement.

An offer for Patent Licensing

New use as antivirals for a family of chemical compounds

Currently, we are witnessing an increase in emerging and re-emerging viral diseases worldwide. In fact, infectious diseases are one of the greatest concerns of both human and veterinary public health. Such is the case of the Ebola virus disease, which is very serious and contagious, causing hemorrhagic fever and with a high mortality rate in humans, which can reach 90%. Although there is already a vaccine, we must never forget that there are people who cannot be vaccinated or have no access to the vaccine and because of this, effective treatments must be available.

In the case of veterinary infections, African swine fever is one of the animal diseases with the greatest socioeconomic repercussions, in China alone in 2019 it accounted for direct losses of 141 billion dollars. The African swine fever virus (ASFV) causes a hemorrhagic disease of high mortality in domestic pigs and wild boars.

The present invention proposes a new use hitherto not described for this family of compounds, as antivirals, which have already been proven effective in vitro against the aforementioned viruses.

Main innovations and advantages

- The present invention relates to the use of these compounds in the treatment and/or prevention of viral diseases. Specifically, they have been tested in vitro for the Ebola virus and African swine fever.
- The therapeutically effective amount of the compound will depend, among other factors, on the individual (human or animal) to be treated, on the severity of the disease suffered by said individual and on the form of administration chosen.

Patent Status
Spanish patent application filed

For more information, please contact:
Marta García Del Barrio, Ph.D.
Centro de Investigaciones Biológicas Margarita Salas.
Deputy Vice-President for Knowledge Transfer of CSIC
Tel.: 34 – 91 8373112 ext. 4255
E-mail: transferencia@cib.csic.es comercializacion@csic.es